Broadening the Discussion on Arrhythmia 4095

ADVERTISING, DISTRIBUTION, & SALES

Treatment for atrial flutter has advanced on many fronts in recent years, and catheter ablation can now be considered a first-line therapy. Until recently, however, most patients were still being managed primarily with long-term drug therapy and missing out on the benefits of catheter ablation, which include a better success rate, increased quality of life, lower recurrence of flutter, and a lower need for rehospitalization upon follow-up.

Boston Scientific Corp. (Natick, MA), a leader in cardiac ablation catheters, teamed up with Adair-Greene Healthcare Communications (Atlanta) to gain a greater understanding of the cardiologistelectrophysiologist relationship as it relates to referring patients for ablation procedures. With this knowledge, the firms created an outreach program designed to connect cardiologists and electrophysiologists and to raise awareness of catheter ablation therapy for flutter and its greater-than-90% success rate.

The company's three-pronged strategy consists of nonpromotional educational tools delivered by key opinion leaders that challenge treatment paradigms, and promotional programs designed to increase awareness of ablation therapy benefits and direct cardiologists to electrophysiologists. Educating flutter patients on the potential benefits of ablation procedures constitutes the third arm of the company's "Arrhythmia in Practice Today" program.

Copyright ©2006 MX